Literature DB >> 1930684

Transcriptional regulation of the HLA-DRA gene.

J P Cogswell1, N Zeleznik-Le, J P Ting.   

Abstract

Class II Major Histocompatibility Complex (MHC) products are essential initiators of cellular immune responses. Their cell surface expression demonstrates aspects of tissue-restricted, inducible, differentiation-dependent, and coordinate regulation indicative of complex molecular controls mediated primarily at the level of transcription. This article reviews our current understanding of transcriptional regulation of one such human class II MHC gene, DRA. Considerable effort has been exerted toward characterizing the cis-acting regulatory sequences and trans-acting DNA binding proteins responsible for regulating DRA transcription. Recent application of novel molecular techniques has resulted in the cloning and characterization of some of these regulatory proteins. A model is presented herein which accommodates the current knowledge of DRA gene regulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1930684

Source DB:  PubMed          Journal:  Crit Rev Immunol        ISSN: 1040-8401            Impact factor:   2.214


  17 in total

1.  Mutations in the bare lymphocyte syndrome define critical steps in the assembly of the regulatory factor X complex.

Authors:  N Nekrep; N Jabrane-Ferrat; B M Peterlin
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  Physical and functional interaction between the human T-cell lymphotropic virus type 1 Tax1 protein and the CCAAT binding protein NF-Y.

Authors:  C A Pise-Masison; J Dittmer; K E Clemens; J N Brady
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Complex architecture of major histocompatibility complex class II promoters: reiterated motifs and conserved protein-protein interactions.

Authors:  N Jabrane-Ferrat; J D Fontes; J M Boss; B M Peterlin
Journal:  Mol Cell Biol       Date:  1996-09       Impact factor: 4.272

4.  Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Yujin Hoshida; Shakti Ramkissoon; Lori Ramkissoon; Benjamin Rich; Cecile L Maire; Brenton R Paolella; Steven E Schumacher; Barbara Tabak; Ruben Ferrer-Luna; Memet Ozek; Aydin Sav; Sandro Santagata; Patrick Yung Wen; Liliana C Goumnerova; Azra H Ligon; Charles Stiles; Rosalind Segal; Todd Golub; Jacques Grill; Keith L Ligon; Jennifer A Chan; Mark W Kieran; Rameen Beroukhim
Journal:  Neuro Oncol       Date:  2015-03-29       Impact factor: 12.300

5.  Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.

Authors:  N Nekrep; M Geyer; N Jabrane-Ferrat; B M Peterlin
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 6.  Current concepts in DRA gene regulation.

Authors:  J P Ting
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

7.  Locus- and allele-specific DNA-protein interactions in the HLA-DQB1 X box.

Authors:  T L Sukiennicki; L M Shewey; G T Nepom
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

8.  Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma.

Authors:  H T Lu; J L Riley; G T Babcock; M Huston; G R Stark; J M Boss; R M Ransohoff
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  Zebrafish Mhc class II alpha chain-encoding genes: polymorphism, expression, and function.

Authors:  H Sültmann; W E Mayer; F Figueroa; C O'hUigin; J Klein
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

10.  Human parainfluenza virus type 3 up-regulates major histocompatibility complex class I and II expression on respiratory epithelial cells: involvement of a STAT1- and CIITA-independent pathway.

Authors:  J Gao; B P De; A K Banerjee
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.